Selected Publications

1. Voskuilen, C.S., et al., Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Carcinoma. Am J Surg Pathol, 2019.

2. Oo, H.Z., et al., Post-translational modifications in bladder cancer: Expanding the tumor target repertoire. Urol Oncol, 2018.

3. Zhai, B., et al., Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination. Cell Death Dis, 2018. 9(10): p. 1016.

4. Agerbæk, M., et al., The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner. Nat Commun, 2018. 9(1): p. 3279.

5. Seiler, R., et al., An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. Eur Urol, 2017. 72(1): p. 142-150.

6. Ayres Pereira, M., et al., Placental Sequestration of Plasmodium falciparum Malaria Parasites Is Mediated by the Interaction Between VAR2CSA and Chondroitin Sulfate A on Syndecan-1. PLoS Pathog, 2016. 12(8): p. e1005831.

7. Clausen, T.M., et al., Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility. Mol Cancer Res, 2016. 14(12): p. 1288-1299.

8. Clausen, T.M., et al., Real-time and label free determination of ligand binding-kinetics to primary cancer tissue specimens; a novel tool for the assessment of biomarker targeting. Sens Biosensing Res, 2016. 9: p. 23-30.

9. Salanti, A., et al., Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. Cancer Cell, 2015. 28(4): p. 500-514.